Autres langues Wave Life Sciences Ltd.

Actions

WVE

SG9999014716

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 24/04/2024			Varia. 5j.	Varia. 1 janv.
5,01 ^USD	-1,38 %		+4,59 %	-0,79 %

23/04	Wave Life Sciences Ltd. annonce un élan continu dans la collaboration avec GSK et des progrès dans les domaines de l'ARNsi et de l'édition de l'ARN	CI
12/03	WAVE LIFE SCIENCES LTD. : Mizuho Securities favorable sur le dossier	ZM

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Wave Life Sciences Announces Continued Momentum in GSK Collaboration and Advancements in siRNA and RNA Editing	23/04
Wave Life Sciences Ltd. Announces Continued Momentum in GSK Collaboration and Advancements in siRNA and RNA Editing	23/04
Wave Life Sciences to Present at Upcoming Investor Conferences	27/03
Sector Update: Health Care Stocks Higher Late Afternoon	06/03
WAVE Life Sciences Shares Surge After Q4 Beats Estimates	06/03
Wave Life Sciences: Q4 Earnings Snapshot	06/03
Wave Life Sciences Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	06/03
Wave Life Sciences Ltd. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	06/03
Earnings Flash (WVE) WAVE LIFE SCIENCES USA Reports Q4 Revenue $29.1M, vs. Street Est of $19.8M	06/03
Wave Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	06/03
Wave Life Sciences Fourth Quarter and Full Year 2023 Financial Results Scheduled for March 6, 2024	28/02
Wave Life Sciences Announces Upcoming Presentations at MDA Conference that Highlight Best-in-Class Potential for WVE-N531 in Duchenne Muscular Dystrophy	27/02
Wave Life Sciences Highlights Recent Achievements and Upcoming 2024 Milestones	08/01
Wave Life Sciences to Present at 42nd Annual J.P. Morgan Healthcare Conference	03/01
Wave Life Sciences Announces Initiation of Dosing in Phase 2 FORWARD-53 Trial of WVE-N531 in Duchenne Muscular Dystrophy	18/12
Wave Life Sciences Starts Dosing in Neuromuscular Disorder Study	15/12
Wave Life Sciences Announces Initiation of Dosing in Phase 2 FORWARD-53 Trial of WVE-N531 in Duchenne Muscular Dystrophy	15/12
Wave Life Sciences Announces Initiation of Dosing in Phase 2 FORWARD-53 Trial of WVE-N531 in Duchenne Muscular Dystrophy	15/12
Sector Update: Health Care Stocks Mixed Pre-Bell Thursday	07/12
Sector Update: Health Care	07/12

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Wave Life Sciences Ltd.

Actions

WVE

SG9999014716

Autres langues

Filtres